{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:47:11Z","timestamp":1791924431859,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["In Vitro Cell.Dev.Biol.-Animal"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s11626-024-00895-2","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T18:02:05Z","timestamp":1712599325000},"page":"321-332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["High yield killing of lymphoma cells by anti-CD22 CAR-NK cell therapy"],"prefix":"10.1007","volume":"60","author":[{"given":"Mahnoosh","family":"Abbaszade Dibavar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Soleimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hossein","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina Soufi","family":"Zomorrod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"key":"895_CR1","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1182\/hematology.2020002547","volume":"2020","author":"R Basar","year":"2020","unstructured":"Basar R, Daher M, Rezvani K (2020) Next-generation cell therapies: the emerging role of CAR-NK cells. Hematology 2020:570\u2013578. https:\/\/doi.org\/10.1182\/hematology.2020002547","journal-title":"Hematology"},{"key":"895_CR2","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.3390\/cells10123390","volume":"10","author":"A Bashiri Dezfouli","year":"2021","unstructured":"Bashiri Dezfouli A, Yazdi M, Pockley AG et al (2021) NK cells armed with chimeric antigen receptors (CAR): roadblocks to successful development. Cells 10:3390. https:\/\/doi.org\/10.3390\/cells10123390","journal-title":"Cells"},{"key":"895_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.02873","volume":"10","author":"ABL Colamartino","year":"2019","unstructured":"Colamartino ABL, Lemieux W, Bifsha P et al (2019) Efficient and robust NK-cell transduction with baboon envelope pseudotyped lentivector. Front Immunol 10:1\u20137. https:\/\/doi.org\/10.3389\/fimmu.2019.02873","journal-title":"Front Immunol"},{"key":"895_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cti2.1274","volume":"10","author":"M Daher","year":"2021","unstructured":"Daher M, Melo Garcia L, Li Y, Rezvani K (2021) CAR-NK cells: the next wave of cellular therapy for cancer. Clin Transl Immunol 10:1\u201316. https:\/\/doi.org\/10.1002\/cti2.1274","journal-title":"Clin Transl Immunol"},{"key":"895_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","volume":"11","author":"M Daher","year":"2021","unstructured":"Daher M, Rezvani K (2021) Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer. Cancer Discov 11:45\u201358. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0556","journal-title":"Cancer Discov"},{"key":"895_CR6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.bbrc.2020.03.071","volume":"527","author":"K Fujiwara","year":"2020","unstructured":"Fujiwara K, Masutani M, Tachibana M, Okada N (2020) Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties. Biochem Biophys Res Commun 527:350\u2013357. https:\/\/doi.org\/10.1016\/j.bbrc.2020.03.071","journal-title":"Biochem Biophys Res Commun"},{"key":"895_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.22037\/ijpr.2021.115089.15193","volume":"20","author":"F Gheidari","year":"2021","unstructured":"Gheidari F, Arefian E, Adegani FJ et al (2021) The miR-142 suppresses U-87 glioblastoma cell growth by targeting EGFR oncogenic signaling pathway. Iran J Pharm Res 20:202\u2013212. https:\/\/doi.org\/10.22037\/ijpr.2021.115089.15193","journal-title":"Iran J Pharm Res"},{"key":"895_CR8","doi-asserted-by":"publisher","first-page":"11855","DOI":"10.1007\/s11033-022-07903-2","volume":"49","author":"F Gheidari","year":"2022","unstructured":"Gheidari F, Arefian E, Saadatpour F et al (2022) The miR-429 suppresses proliferation and migration in glioblastoma cells and induces cell-cycle arrest and apoptosis via modulating several target genes of ERBB signaling pathway. Mol Biol Rep 49:11855\u201311866. https:\/\/doi.org\/10.1007\/s11033-022-07903-2","journal-title":"Mol Biol Rep"},{"key":"895_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2020.1825177","volume":"9","author":"S Grote","year":"2020","unstructured":"Grote S, Mittelstaet J, Baden C et al (2020) Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting. Oncoimmunology 9:1\u201311. https:\/\/doi.org\/10.1080\/2162402X.2020.1825177","journal-title":"Oncoimmunology"},{"key":"895_CR10","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/cas.14799","volume":"112","author":"Z Guo","year":"2021","unstructured":"Guo Z, Tu S, Yu S et al (2021) Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies. Cancer Sci 112:1357\u20131368. https:\/\/doi.org\/10.1111\/cas.14799","journal-title":"Cancer Sci"},{"key":"895_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.intimp.2019.04.057","volume":"73","author":"C Han","year":"2019","unstructured":"Han C, Jiang Y, Wang Z, Wang H (2019) Natural killer cells involved in tumour immune escape of hepatocellular carcinomar. Int Immunopharmacol 73:10\u201316. https:\/\/doi.org\/10.1016\/j.intimp.2019.04.057","journal-title":"Int Immunopharmacol"},{"key":"895_CR12","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","volume":"121","author":"W Haso","year":"2013","unstructured":"Haso W, Lee DW, Shah NN et al (2013) Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121:1165\u20131171. https:\/\/doi.org\/10.1182\/blood-2012-06-438002","journal-title":"Blood"},{"key":"895_CR13","doi-asserted-by":"publisher","unstructured":"Heipertz EL, Zynda ER, Stav-Noraas TE et al (2021) Current perspectives on \u201coff-the-shelf\u201d allogeneic NK and CAR-NK cell therapies. Front Immunol 12:. https:\/\/doi.org\/10.3389\/fimmu.2021.732135","DOI":"10.3389\/fimmu.2021.732135"},{"key":"895_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/cpim.108","volume":"131","author":"L Herrera","year":"2020","unstructured":"Herrera L, Juan M, Eguizabal C (2020) Purification, culture, and CD19-CAR lentiviral transduction of adult and umbilical cord blood NK cells. Curr Protoc Immunol 131:2\u201313. https:\/\/doi.org\/10.1002\/cpim.108","journal-title":"Curr Protoc Immunol"},{"key":"895_CR15","doi-asserted-by":"publisher","unstructured":"Kalos M, Levine BL, Porter DL et al (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3:. https:\/\/doi.org\/10.1126\/scitranslmed.3002842","DOI":"10.1126\/scitranslmed.3002842"},{"key":"895_CR16","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, O\u2019Connor RS, Fraietta JA et al (2016) Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44:380\u2013390. https:\/\/doi.org\/10.1016\/j.immuni.2016.01.021","journal-title":"Immunity"},{"key":"895_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.707542","volume":"12","author":"MB Khawar","year":"2021","unstructured":"Khawar MB, Sun H (2021) CAR-NK cells: from natural basis to design for kill. Front Immunol 12:1\u201322. https:\/\/doi.org\/10.3389\/fimmu.2021.707542","journal-title":"Front Immunol"},{"key":"895_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4161\/onci.28147","volume":"3","author":"H Klingemann","year":"2014","unstructured":"Klingemann H (2014) Are natural killer cells superior CAR drivers? Oncoimmunology 3:37\u201341. https:\/\/doi.org\/10.4161\/onci.28147","journal-title":"Oncoimmunology"},{"key":"895_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cyto.2019.02.001","volume":"117","author":"GM Konjevi\u0107","year":"2019","unstructured":"Konjevi\u0107 GM, Vuleti\u0107 AM, Mirja\u010di\u0107 Martinovi\u0107 KM et al (2019) The role of cytokines in the regulation of NK cells in the tumor environment. Cytokine 117:30\u201340. https:\/\/doi.org\/10.1016\/j.cyto.2019.02.001","journal-title":"Cytokine"},{"key":"895_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0264897","volume":"17","author":"R Kotzur","year":"2022","unstructured":"Kotzur R, Duev-Cohen A, Kol I et al (2022) NK-92 cells retain vitality and functionality when grown in standard cell culture conditions. PLoS One 17:1\u201313. https:\/\/doi.org\/10.1371\/journal.pone.0264897","journal-title":"PLoS One"},{"key":"895_CR21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188\u2013195. https:\/\/doi.org\/10.1182\/blood-2014-05-552729","journal-title":"Blood"},{"key":"895_CR22","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/ajh.26160","volume":"96","author":"S Liu","year":"2021","unstructured":"Liu S, Deng B, Yin Z et al (2021) Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Am J Hematol 96:671\u2013679. https:\/\/doi.org\/10.1002\/ajh.26160","journal-title":"Am J Hematol"},{"key":"895_CR23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF et al (2015) 4\u20131BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21:581\u2013590. https:\/\/doi.org\/10.1038\/nm.3838","journal-title":"Nat Med"},{"key":"895_CR24","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","volume":"17","author":"MC Milone","year":"2009","unstructured":"Milone MC, Fish JD, Carpenito C et al (2009) Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17:1453\u20131464. https:\/\/doi.org\/10.1038\/mt.2009.83","journal-title":"Mol Ther"},{"key":"895_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.03123","volume":"10","author":"S M\u00fcller","year":"2020","unstructured":"M\u00fcller S, Bexte T, Gebel V et al (2020) High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia. Front Immunol 10:1\u201316. https:\/\/doi.org\/10.3389\/fimmu.2019.03123","journal-title":"Front Immunol"},{"key":"895_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/j.1600-065X.2009.00801.x","volume":"230","author":"L Nitschke","year":"2009","unstructured":"Nitschke L (2009) CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol Rev 230:128\u2013143. https:\/\/doi.org\/10.1111\/j.1600-065X.2009.00801.x","journal-title":"Immunol Rev"},{"key":"895_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ebiom.2019.01.018","volume":"39","author":"E Overview","year":"2019","unstructured":"Overview E (2019) Natural killer cells for cancer immunotherapy: a new CAR is catching up. EBioMedicine 39:1\u20132. https:\/\/doi.org\/10.1016\/j.ebiom.2019.01.018","journal-title":"EBioMedicine"},{"key":"895_CR28","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1182\/blood-2018-99-118005","volume":"132","author":"C Quintarelli","year":"2018","unstructured":"Quintarelli C, Sivori S, Caruso S et al (2018) CD19 redirected CAR NK cells are equally effective but less toxic than CAR T cells. Blood 132:3491\u20133491. https:\/\/doi.org\/10.1182\/blood-2018-99-118005","journal-title":"Blood"},{"key":"895_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ (2020) Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol 17:147\u2013167. https:\/\/doi.org\/10.1038\/s41571-019-0297-y","journal-title":"Nat Rev Clin Oncol"},{"key":"895_CR30","doi-asserted-by":"publisher","first-page":"295","DOI":"10.22038\/IJBMS.2023.66903.14675","volume":"26","author":"N Rassaei","year":"2023","unstructured":"Rassaei N, Dibavar MA, Soleimani M et al (2023) The effect of microvesicles derived from K562 cells on proliferation and apoptosis of human bone marrow mesenchymal stem cells. Iran J Basic Med Sci 26:295\u2013300. https:\/\/doi.org\/10.22038\/IJBMS.2023.66903.14675","journal-title":"Iran J Basic Med Sci"},{"key":"895_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-022-03326-6","volume":"20","author":"G Roex","year":"2022","unstructured":"Roex G, Campillo-Davo D, Flumens D et al (2022) Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. J Transl Med 20:1\u201313. https:\/\/doi.org\/10.1186\/s12967-022-03326-6","journal-title":"J Transl Med"},{"key":"895_CR32","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/jcmm.12810","volume":"20","author":"A Romanski","year":"2016","unstructured":"Romanski A, Uherek C, Bug G et al (2016) CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med 20:1287\u20131294. https:\/\/doi.org\/10.1111\/jcmm.12810","journal-title":"J Cell Mol Med"},{"key":"895_CR33","doi-asserted-by":"publisher","unstructured":"Savani M, Oluwole O, Dholaria B (2021) New targets for CAR T therapy in hematologic malignancies. Best Pract Res Clin Haematol 34:. https:\/\/doi.org\/10.1016\/j.beha.2021.101277","DOI":"10.1016\/j.beha.2021.101277"},{"key":"895_CR34","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/mt.2014.219","volume":"23","author":"K Sch\u00f6nfeld","year":"2015","unstructured":"Sch\u00f6nfeld K, Sahm C, Zhang C et al (2015) Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2\/HER2-specific chimeric antigen receptor. Mol Ther 23:330\u2013338. https:\/\/doi.org\/10.1038\/mt.2014.219","journal-title":"Mol Ther"},{"key":"895_CR35","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/pbc.25410","volume":"62","author":"NN Shah","year":"2015","unstructured":"Shah NN, Stevenson MS, Yuan CM et al (2015) Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr Blood Cancer 62:964\u2013969. https:\/\/doi.org\/10.1002\/pbc.25410","journal-title":"Pediatr Blood Cancer"},{"key":"895_CR36","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","volume":"27","author":"JY Spiegel","year":"2021","unstructured":"Spiegel JY, Patel S, Muffly L et al (2021) CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med 27:1419\u20131431. https:\/\/doi.org\/10.1038\/s41591-021-01436-0","journal-title":"Nat Med"},{"key":"895_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000445325","volume":"43","author":"G Suck","year":"2016","unstructured":"Suck G, Linn YC, Tonn T (2016) Natural killer cells for therapy of leukemia. Transfus Med Hemotherapy 43:89\u201395. https:\/\/doi.org\/10.1159\/000445325","journal-title":"Transfus Med Hemotherapy"},{"key":"895_CR38","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jcyt.2020.12.007","volume":"23","author":"J Tanaka","year":"2021","unstructured":"Tanaka J (2021) Recent advances in cellular therapy for malignant lymphoma. Cytotherapy 23:662\u2013671. https:\/\/doi.org\/10.1016\/j.jcyt.2020.12.007","journal-title":"Cytotherapy"},{"key":"895_CR39","doi-asserted-by":"publisher","unstructured":"Wang L, Qin W, Huo YJ et al (2020) Advances in targeted therapy for malignant lymphoma. Signal Transduct Target Ther 5:. https:\/\/doi.org\/10.1038\/s41392-020-0113-2","DOI":"10.1038\/s41392-020-0113-2"},{"key":"895_CR40","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2217\/imt-2017-0022","volume":"9","author":"WN Wang","year":"2017","unstructured":"Wang WN, Zhou GY, Zhang WL (2017) NK-92 cell, another ideal carrier for chimeric antigen receptor. Immunotherapy 9:753\u2013765. https:\/\/doi.org\/10.2217\/imt-2017-0022","journal-title":"Immunotherapy"},{"key":"895_CR41","doi-asserted-by":"publisher","first-page":"354","DOI":"10.5582\/bst.2020.03308","volume":"14","author":"J Xia","year":"2020","unstructured":"Xia J, Minamino S, Kuwabara K (2020) CAR-expressing NK cells for cancer therapy: a new hope. Biosci Trends 14:354\u2013359. https:\/\/doi.org\/10.5582\/bst.2020.03308","journal-title":"Biosci Trends"},{"key":"895_CR42","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4161\/mabs.1.3.8113","volume":"1","author":"X Xiao","year":"2009","unstructured":"Xiao X, Ho M, Zhu Z et al (2009) Identification and characterization of fully human anti-CD22 monoclonal antibodies. Mabs 1:297\u2013303. https:\/\/doi.org\/10.4161\/mabs.1.3.8113","journal-title":"Mabs"},{"key":"895_CR43","doi-asserted-by":"publisher","first-page":"13991","DOI":"10.18632\/oncotarget.24179","volume":"9","author":"D Xu","year":"2018","unstructured":"Xu D, Jin G, Chai D et al (2018) The development of CAR design for tumor CAR-T cell therapy. Oncotarget 9:13991\u201314004. https:\/\/doi.org\/10.18632\/oncotarget.24179","journal-title":"Oncotarget"}],"container-title":["In Vitro Cellular & Developmental Biology - Animal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11626-024-00895-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11626-024-00895-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11626-024-00895-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T14:09:54Z","timestamp":1715004594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11626-024-00895-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["895"],"URL":"https:\/\/doi.org\/10.1007\/s11626-024-00895-2","relation":{},"ISSN":["1071-2690","1543-706X"],"issn-type":[{"value":"1071-2690","type":"print"},{"value":"1543-706X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"6 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was approved by Ethical Committee of Shahid Beheshti University of Medical Sciences (IR.SBMU.RETECH.REC.1402.158) (Approval date: 11\/06\/2023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest regarding the publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}